Ors had a Methyl phenylacetate Epigenetic Reader Domain higher percentage of DDR mutations than kind I tumors (70.59 vs. 28.85 , p 0.001, chi-squared test). The advancedBiomedicines 2021, 9,9 ofstage sufferers had greater percentage of DDR mutations than the early-stage individuals (57.28 vs. 27.54 , p 0.001, chi-squared test). Recurring individuals had a 1-Phenylethan-1-One Purity & Documentation larger percentage of DDR mutations than those without the need of recurrence (53.92 vs. 32.86 , p = 0.006, chi-squared test). Individuals who died of EOC had a larger percentage of DDR mutations than living sufferers (59.21 vs. 34.38 , p = 0.001, chi-squared test). EOC sufferers without DDR gene mutation had longer progression-free survival (PFS) (p = 0.0072, log-rank test, Figure 2A) and general survival (OS) (p = 0.022, log-rank test, Figure 2B) than these with 1 DDR or two DDR mutations. In serous carcinoma, sufferers with or without DDR mutations had equivalent PFS (p = 0.56, log-rank test, Figure 2C). Individuals with two DDR mutations had a trend of better OS than these with 1 mutation or none, nevertheless it was not statistically significant (p = 0.47, log-rank test, Figure 2D). In endometrioid carcinoma, patients with 2 DDR gene mutations had shorter PFS (p = 0.0035, log-rank test, Figure 2E) and OS (p = 0.015, log-rank test, Figure 2F) than these with 1 mutation or none. In clear cell carcinoma, individuals with two DDR gene mutations had substantially shorter PFS (p = 0.0056, log-rank test, Figure 2G) and OS (p = 0.0046, log-rank test, Figure 2H) than these with 1 DDR mutation or none. Tumor recurrence with CCR gene mutation (HR: 1.68 (1.12.50), p = 0.011), 1 DDR gene mutation (HR: 1.71 (1.12.60), p = 0.013), endometrioid carcinoma (HR: 0.17 (0.08.37), p 0.001), kind II tumor (HR: two.69 (1.81.00), p 0.001), advanced-stage carcinoma (HR: five.29 (three.16.85), p 0.001), high-grade tumor (HR: 5.57 (2.263.70), p 0.001) and optimal debulking surgery (HR: 0.28 (0.18.41), p 0.001) have been considerable within the univariate Cox regression model (Table 5). Advanced-stage carcinoma (HR: three.08 (1.63.80), p = 0.001) and optimal debulking surgery (HR: 0.51 (0.32.80), p = 0.004) had been important prognostic factors inside the multivariate evaluation. Cancer-related death with TLS gene mutation (HR: 33.76 (three.9589.00), p = 0.001), 1 DDR gene mutation (HR: 1.96 (1.20.20), p = 0.007), endometrioid carcinoma (HR: 0.12 (0.04.38), p 0.001), variety II tumor (HR: 1.88 (1.19.96), p = 0.007), advanced-stage carcinoma (HR: six.84 (three.284.25), p 0.001), high-grade tumor (HR: 17.97 (2.5029.29), p = 0.004) and optimal debulking surgery (HR: 0.26 (0.16.41), p 0.001) have been considerable within the univariate Cox regression model. Sort II tumor (HR: 0.35 (0.20.60), p 0.001), TLS gene mutation (HR: 9.57 (1.084.83), p = 0.042), advanced-stage carcinoma (HR: four.82 (2.091.09), p 0.001) and optimal debulking surgery (HR: 0.38 (0.22.64), p 0.001) had been vital prognostic elements inside the multivariate analysis.Biomedicines 2021, 9,ten ofTable four. The correlation of DDR gene mutations with clinical parameters inside the epithelial ovarian cancer individuals. Genes OSA Total HR Wild sort Mutation p worth NHEJ Wild form Mutation p value MMR Wild form Mutation p value BER Wild kind Mutation p value 160 93.02 12 6.98 65 94.20 four five.80 37 94.87 2 5.13 58 90.63 6 9.38 0.631 96 92.31 eight 7.69 64 94.12 4 5.88 0.649 65 94.20 4 five.80 95 92.23 8 7.77 0.619 27 93.10 two 6.90 133 93.01 10 six.99 0.985 66 94.29 four five.71 94 92.16 eight 7.84 0.59 91 94.79 five five.21 69 90.79 7 9.21 0.306 161 93.60 11 six.40 67 97.10 two two.90 33 84.62 six 15.38 61.
